We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Adjuvants for Immunotherapy and Vaccine Development

App Note / Case Study  
Published: July 20, 2021
 
|  Last Updated: July 20, 2021
Adjuvants for Immunotherapy and Vaccine Development content piece image

Whether you specialize in lipidomics, or lipids are a regular part of your research, you will know the critical role they play. For example, adjuvants using heterogeneous monophosphoryl Lipid A (MPL) derived from Salmonella minnesota R595, have proven to be safe and effective at inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines. While adjuvant systems play a key part in immunotherapy and vaccine development programs, adjuvant formulation can be a costly and time-consuming process. Partnering with a company with expertise in lipid formulation can help to relieve this burden.

Download this flyer to discover:

  • Various monophosphoryl lipid A (MPLA) adjuvants
  • A trehalose dibehenate and DDA adjuvant system for tuberculosis vaccines
Related Topic Pages
Infectious Diseases
The Immune System
Food and Beverage Analysis
Vaccine Design and Testing
Advertisement
Chosen for You
A technician using a precision balance to weigh powdered samples on a weighing boat, showcasing accurate measurements in a lab.
Whitepaper

How To Get the Most Out of Your Analytical Balance
Researcher in a lab using a pipette and 96-well plate for cell culture or assay analysis, highlighting hands-on lab work
Whitepaper

Advances in CHO Cell Line Development for Biotherapeutics
A bright blue vial and a DNA helix on a dark blue background, with the evotec logo in the corner.
Webinar

Harnessing microRNAs To Direct Bone and Cartilage Repair
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter